Search Bar & Filters
Found 5 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating remibrutinib for its effectiveness and safety in treating patients with secondary progressive multiple sclerosis SPMS. This Phase III, randomized, double-blind, placebo-controlled study involves about 1275 participants who meet specific criteria, including an SPMS diagnosis and disability progression. The trial is designed to provide detailed data on remibrutinibs impact compared to placebo, with a focus on disability progression and other neurological measures. Participants are randomly assigned to receive either remibrutinib or a matching placebo tablet during the Core Part of the study, which is event-driven and double-blind. Following this, there is an Extension Part where all participants receive open-label remibrutinib tablets. Treatment is oral and involves ongoing monitoring to assess long-term effects and safety. Throughout the study, participants will undergo regular assessments including disability evaluations using the Expanded Disability Status Scale EDSS, Timed 25-Foot Walk, 9-Hole Peg Test, and cognitive testing with the Symbol Digit Modalities Test SDMT. Brain imaging will be used to track lesion development and brain atrophy. Safety will be closely monitored by recording adverse events. The total participation may span up to approximately five years, covering both core and extension phases.
Actively Recruiting
Researchers are conducting an international, multicenter, prospective, non-randomized observational study to confirm and support the clinical safety and performance of the Coroflex ISAR NEO coronary stent system. This study focuses on patients with coronary artery disease CAD or ischemic heart disease treated in real-world clinical settings to meet European Union Medical Device Regulation requirements for post-market follow-up. It involves consecutive patients treated with the sirolimus-eluting Coroflex ISAR NEO stent as intended by the manufacturer. Participants receive the Coroflex ISAR NEO coronary stent system during their routine percutaneous coronary intervention PCI procedures. This study observes patients undergoing stent placement according to standard clinical recommendations, without randomization or specific treatment assignment. The study includes patients with new lesion lengths between 2 and 4 mm and follows them after stent implantation to monitor outcomes and device performance. During the study, participants are monitored for safety and effectiveness outcomes including freedom from target lesion failure within seven days after the procedure. Additional assessments track potential complications during PCI such as accidental stent dislodgement, balloon or hypotube rupture, coronary perforation, dissection, no reflow, and thrombosis. Data collection continues according to clinical practice, with informed consent obtained and follow-up lasting up to the study completion date in February 2027.
Actively Recruiting
This research aims to study people who have had their first episode of symptomatic deep vein thrombosis DVT in their lower limbs to understand the risk and severity of post-thrombotic syndrome PTS, the most common long-term complication of DVT. The study focuses on evaluating how the amount of thrombosis blood clot burden measured by the Venous Volumetric Index VVI on ultrasound relates to the development and severity of PTS assessed by the Villalta scale over 6 months. Participants will be followed at multiple times around 1 week, 1 month, 3 months, and 6 months after diagnosis. At each visit, doctors will assess symptoms and signs to calculate the Villalta score and perform venous ultrasounds to measure thrombosis burden using the VVI. Blood samples will be collected at several visits to study inflammation, coagulation, and clot breakdown factors. Quality of life questionnaires will also be completed at 3 and 6 months. During the study, symptom assessments, ultrasound exams, blood tests, and questionnaires will help researchers understand how the thrombosis burden at baseline and over time relates to the occurrence and severity of PTS. The study ends with the 6-month visit. Researchers will monitor the presence of moderate to severe PTS and changes in clot burden to identify important prognostic factors that may guide future prevention and treatment strategies.
Actively Recruiting
Researchers are evaluating the impact of different fluid removal strategies in intensive care unit ICU patients with acute kidney injury AKI who are receiving renal replacement therapy RRT. The goal is to see if a higher rate of fluid removal net ultrafiltration guided by tissue perfusion parameters can improve overall health outcomes compared to a lower, stabilizing fluid removal rate. This study aims to address the risks of fluid overload, which is linked to worse health outcomes, and balance it with the risk of reduced blood volume that can cause tissue damage. Participants are randomly assigned to one of two groups. The experimental group receives a higher ultrafiltration rate of 2 mlkgh to reduce fluid overload until the patients baseline body weight is reached, with adjustments based on tolerance and tissue perfusion. The control group receives a lower ultrafiltration rate between 0 and 1 mlkgh aimed at stabilizing fluid balance without targeting weight loss. In case of intolerance or failure to reach targets, ultrafiltration rates are adjusted accordingly. During the study, patients are monitored closely for organ function, fluid balance, and tissue perfusion. Researchers will assess outcomes such as days free from organ support, kidney recovery, time on ventilator and vasopressors, ICU stay length, and occurrence of complications like arrhythmias or intestinal ischemia. The primary outcome is the number of organ replacement-free days by day 30. The study involves randomization, single masking, and will continue until January 2028.
Actively Recruiting
Healthy Volunteer
Cancer treatment often involves surgery, chemotherapy, and radiotherapy, which can cause acute and chronic pain, including neuropathic pain that is hard to predict and treat. Many cancer patients experience chronic pain that significantly affects their quality of life. This research aims to validate a predictive tool to assess the risk of neuropathic pain and pain chronicity in cancer patients, considering factors like preoperative pain, opioid use, age, sleep, psychological state, and social vulnerability. The study involves 500 cancer patients with breast, gynecological, lung, or colorectal cancers, along with 125 healthy volunteers as controls. Participants will undergo assessments of cognitive, emotional, and pain-related factors through questionnaires. Data collection occurs at baseline, 6 months, and 12 months to evaluate pain intensity, neuropathic pain signs, cognitive function, emotional status, social vulnerability, quality of life, sleep quality, disease perception, and analgesic use. Participants will complete various validated questionnaires and scales at these time points to help researchers measure their pain trajectories and related factors. The primary outcome is the CANoPy score, assessed at baseline and during follow-up visits. The study tracks these measures over one year to understand pain development and its impact, aiming to improve predictive abilities for neuropathic pain in cancer management.